Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Esmolol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 3/20 | 0.97 |
| ▸ | ADRB1 known ✓ | P08588 | 3/20 | 0.97 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.69 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.69 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.69 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.66 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.66 |
| ▸ | NPY1R | P25929 | 1/20 | 0.66 |
| ▸ | NPY2R | P49146 | 1/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.66 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | CNR1 | P21554 | 1/20 | 0.64 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.64 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | GLA | P06280 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Esmolol SCHEMBL30039548 | 1.00 | ADRB2 (0.97) | ADRB2ADRB1ADRA1ANR3C1CYP2D6 | |
| Esmolol SCHEMBL41088 | 1.00 | ADRB2 (0.97) | ADRB2ADRB1ADRA1ANR3C1CYP2D6 | |
| Esmolol SCHEMBL3605 | 0.99 | ADRB2 (1.00) | ADRB2ADRB1ADRA1ANR3C1CYP2D6 | |
| Esmolol SCHEMBL3607 | 0.99 | ADRB2 (1.00) | ADRB2ADRB1ADRA1ANR3C1CYP2D6 | |
| Esmolol SCHEMBL6509147 | 0.99 | ADRB2 (1.00) | ADRB2ADRB1ADRA1ANR3C1CYP2D6 | |
| Esmolol SCHEMBL3606 | 0.99 | ADRB2 (1.00) | ADRB2ADRB1ADRA1ANR3C1CYP2D6 | |
| Esmolol SCHEMBL28687772 | 0.97 | ADRB2 (0.97) | ADRB2ADRB1ADRA1ANR3C1CYP2D6 | |
| Esmolol SCHEMBL27879439 | 0.96 | ADRB2 (0.91) | ADRB2ADRB1ADRA1ANR3C1CYP2D6 | |
| Esmolol SCHEMBL1649927 | 0.96 | ADRB2 (0.95) | ADRB2ADRB1ADRA1ANR3C1CYP2D6 | |
| Esmolol SCHEMBL9751334 | 0.95 | ADRB2 (0.93) | ADRB2ADRB1ADRA1ANR3C1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2852 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120121761-A | Method for detecting epichlorohydrin content in esmolol sample | 浙江省食品药品检验研究院(《中国现代应用药学》杂志社) | 2025-06-10 | — | — | CN | claimed |
| CN-119732912-A | Esmolol hydrochloride freeze-dried powder, preparation method and application thereof | 华夏生生药业(北京)有限公司 | 2025-04-01 | — | — | CN | claimed |
| US-20250090501-A1 | METHODS OF TREATING GUT MOTILITY DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-03-20 | — | — | US | claimed |
| CN-119619349-A | Liquid chromatography detection method for related substances in esmolol hydrochloride injection | 华夏生生药业(北京)有限公司 | 2025-03-14 | — | — | CN | claimed |
| CN-119613359-A | Preparation of esmolol hydrochloride key intermediate | 广东京豪生物制药有限公司 | 2025-03-14 | — | — | CN | claimed |
| CN-119613358-A | Preparation process of esmolol hydrochloride | 广东京豪生物制药有限公司 | 2025-03-14 | — | — | CN | claimed |
| CN-115951003-B | Method for detecting impurity of esmolol hydrochloride injection | 湖南省药品检验检测研究院 | 2024-12-24 | — | — | CN | claimed |
| CN-118557516-A | Pharmaceutical composition containing esmolol hydrochloride and preparation method thereof | 湖南赛隆药业(长沙)有限公司 | 2024-08-30 | — | — | CN | claimed |
| CN-118561702-A | Preparation process of esmolol hydrochloride | 湖南赛隆药业(长沙)有限公司 | 2024-08-30 | — | — | CN | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| US-20030069221-A1 | Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions | SCHERING CORPORATION | 2003-04-10 | — | — | US | claimed |
| US-6528540-B2 | Administering by injection | BAXTER INTERNATIONAL INC. | 2003-03-04 | — | — | US | claimed |
| US-20020147239-A1 | Esmolol formulation | BAXTER INTERNATIONAL INC. (US) | 2002-10-10 | — | — | US | claimed |
| WO-2002076446-A1 | ESMOLOL FORMULATION | BAXTER INTERNATIONAL INC. (US) | 2002-10-03 | — | — | WO | claimed |
| US-6429217-B1 | ADMINISTERING ACETYLCHOLINESTERASE INHIBITOR, BETA-ADRENERGIC RECEPTOR BLOCKER AND CALCIUM CHANNEL BLOCKER TO CONTROL HEARTBEAT DURING HEART SURGERY; MINIMIZES GRAFT FAILURE | EMORY UNIVERSITY | 2002-08-06 | — | — | US | claimed |
| WO-2002058731-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH CARDIOVASCULAR AGENT(S) FOR THE TREATMENT OF VASCULAR CONDITIONS | SCHERING CORPORATION (US) | 2002-08-01 | — | — | WO | claimed |
| CN-1074763-C | Process for synthesizing and refining esmolol hydrochloride | SHANDONG PROV PHARMACEUTICAL I (CN) | 2001-11-14 | — | — | CN | claimed |
| US-6310094-B1 | INJECTABLE AQUEOUS PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CARDIAC CONDITIONS, HAVING PH BETWEEN 3.5 AND 6.5, COMPRISING ESMOLOL HYDROCHLORIDE, BUFFERING AGENT AND OSMOTIC-ADJUSTING AGENT | BAXTER INTERNATIONAL INC. | 2001-10-30 | — | — | US | claimed |
| CN-1217320-A | Process for synthesizing and refining esmolol hydrochloride | SHANDONG PROV PHARMACEUTICAL I (CN) | 1999-05-26 | — | — | CN | claimed |
| EP-0403578-B1 | STABLE PHARMACEUTICAL COMPOSITION | OHMEDA (GB) | 1994-10-12 | — | — | EP | claimed |